SCHEMBL5163367

SCHEMBL5163367

O=C(CC(=O)N1CCCCC1)c1cc2ccccc2o1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.68
HPGD P15428 2/20 0.68
L3MBTL1 Q9Y468 1/20 0.68
MAPT P10636 3/20 0.66
POLB P06746 1/20 0.66
FLT3 P36888 1/20 0.54
KDM4E B2RXH2 3/20 0.53
GRIN2B Q13224 1/20 0.52
HRH4 Q9H3N8 1/20 0.51
NPC1 O15118 6/20 0.51
RAB9A P51151 5/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
KMT2A Q03164 2/20 0.51
TP53 P04637 1/20 0.51
HTT P42858 1/20 0.51
ATM Q13315 1/20 0.51
NPSR1 Q6W5P4 1/20 0.51
LMNA P02545 1/20 0.50
MEN1 O00255 1/20 0.49
TSHR P16473 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5161361 0.99 MAPT (0.68) ALDH1A1HPGDL3MBTL1MAPTPOLB
SCHEMBL19864572 0.81 ALDH1A1 (1.00) ALDH1A1HPGDL3MBTL1MAPTPOLB
SCHEMBL15170873 0.81 ALDH1A1 (1.00) ALDH1A1HPGDL3MBTL1MAPTPOLB
SCHEMBL5158485 0.76 FLT3 (0.62) ALDH1A1HPGDL3MBTL1MAPTFLT3
SCHEMBL3032755 0.75 FLT3 (0.61) ALDH1A1HPGDL3MBTL1MAPTFLT3
SCHEMBL5774148 0.74 MAPT (0.68) ALDH1A1HPGDL3MBTL1MAPTPOLB
SCHEMBL5161032 0.73 DPP4 (0.51) ALDH1A1HPGDL3MBTL1MAPTKDM4E
SCHEMBL10155752 0.73 FLT3 (0.67) ALDH1A1HPGDL3MBTL1MAPTFLT3
SCHEMBL28117952 0.73 FLT3 (0.67) ALDH1A1HPGDL3MBTL1MAPTPOLB
SCHEMBL10313745 0.73 FLT3 (0.67) ALDH1A1HPGDL3MBTL1MAPTPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8293899-B2 Ketone transfer hydrogenation of stereoisomerically enriched 3-heteroaryl-3-oxocarboxylic esters by reducing 3-heteroaryl-3-hydroxycarboxylic esters in the presence of a ruthenium-containing catalyst, an amine and formic acid and/or formates LANXESS DEUTSCHLAND GMBH (DE) 2012-10-23 US disclosed
EP-1340746-B1 Process for the reduction of 3-heteroaryl-3-oxo-propanoic acid derivatives SALTIGO GMBH (DE) 2007-02-28 EP disclosed
US-20030225274-A1 Process for reducing 3-heteroaryl-3-oxopropionic acid derivatives LANXESS DEUTSCHLAND GMBH (DE) 2003-12-04 US disclosed
EP-1340746-A1 Process for the reduction of 3-heteroaryl-3-oxo-propanoic acid derivatives BAYER AG (DE) 2003-09-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225274-A1 Process for reducing 3-heteroaryl-3-oxopropionic acid derivatives GRHPR, HPD, HAAO ALDH1A1 273/4885HPGD 673/4885L3MBTL1 4382/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.